Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma
Taken together, this work demonstrates the utility of extending CARPOOL to diseases beyond hematological malignancies and represents the largest exploration of signaling combinations in human primary cells to date.
Authors
- Michael E. Birnbaum (ORCID: https://orcid.org/0000-0002-2281-3518)
- Khloe S. Gordon (ORCID: https://orcid.org/0000-0003-3652-7245)
- Maxine Lam
- Caleb R. Perez (ORCID: https://orcid.org/0000-0001-8709-6145)
- Andrea Pavesi (ORCID: https://orcid.org/0000-0003-2777-1043)
- Douglas A. Lauffenburger (ORCID: https://orcid.org/0000-0002-0050-989X)
- Anisha Datta
- Andrea Garmilla (ORCID: https://orcid.org/0000-0002-5093-1423)
- Joey Aw
Institutions
- Agency for Science, Technology and Research (SG)
- Harvard University (US)
- Nanyang Technological University (SG)
- Singapore-MIT Alliance for Research and Technology (SG)
- Massachusetts Institute of Technology (US)
- Institute of Molecular and Cell Biology (SG)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-009574
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- National Science Foundation
- David and Lucile Packard Foundation
- Pew Charitable Trusts
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Research Foundation
- Agency for Science, Technology and Research
- National Research Foundation Singapore
- Deshpande Center for Technological Innovation, Massachusetts Institute of Technology
- Institute of Molecular and Cell Biology
- National Cancer Institute
- National Institute of General Medical Sciences
- Army Research Office
- Army Research Laboratory